A Study of Eptinezumab in Pediatric Participants With Episodic Migraine

Recruiting

Phase 3

A Study of Eptinezumab in Pediatric Participants With Episodic MigraineA Study of Eptinezumab in Pediatric Participants With Episodic Migraine

Sponsor:

H. Lundbeck A/S

Code:

NCT05897320

Conditions

Episodic Migraine

Eligibility Criteria

Sex: All

Age: 6 - 17

Healthy Volunteers: Not accepted

Interventions

Eptinezumab

Placebo

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-03-25. This information was provided to ClinicalTrials.gov by H. Lundbeck A/S on 2025-02-14.